BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 28314991)

  • 21. The role of expression and polymorphism of the BAG-1 gene in response to platinum-based chemotherapeutics in NSCLC.
    Wang YD; Ha MW; Cheng J; Zhang WL; Cong X; Tong CY; Sun J
    Oncol Rep; 2012 Apr; 27(4):979-86. PubMed ID: 22179630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression.
    Bartolucci R; Wei J; Sanchez JJ; Perez-Roca L; Chaib I; Puma F; Farabi R; Mendez P; Roila F; Okamoto T; Taron M; Rosell R
    Clin Lung Cancer; 2009 Jan; 10(1):47-52. PubMed ID: 19289372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of XPC, XPD, XPF, and XPG gene polymorphisms on the risk and the outcome of acute myeloid leukemia in a Romanian population.
    Bănescu C; Iancu M; Trifa AP; Dobreanu M; Moldovan VG; Duicu C; Tripon F; Crauciuc A; Skypnyk C; Bogliș A; Lazar E
    Tumour Biol; 2016 Jul; 37(7):9357-66. PubMed ID: 26779634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. XPG gene polymorphisms and cancer susceptibility: evidence from 47 studies.
    Huang J; Liu X; Tang LL; Long JT; Zhu J; Hua RX; Li J
    Oncotarget; 2017 Jun; 8(23):37263-37277. PubMed ID: 28416771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis.
    Tan LM; Qiu CF; Zhu T; Jin YX; Li X; Yin JY; Zhang W; Zhou HH; Liu ZQ
    Sci Rep; 2017 Jul; 7(1):5593. PubMed ID: 28717179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of XPG gene rs751402 polymorphism with gastric cancer risk: a meta-analysis in the Chinese population.
    Liang J; Xu YY; Zhang C; Xia QR
    Int J Biol Markers; 2018 May; 33(2):174-179. PubMed ID: 29148016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine.
    Monzo M; Moreno I; Navarro A; Ibeas R; Artells R; Gel B; Martinez F; Moreno J; Hernandez R; Navarro-Vigo M
    Oncology; 2007; 72(5-6):364-70. PubMed ID: 18204222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. XPG polymorphisms and their association with lung cancer susceptibility, overall survival and response in North Indian patients treated with platinum-based doublet chemotherapy.
    Lawania S; Singh N; Behera D; Sharma S
    Future Oncol; 2019 Jan; 15(2):151-165. PubMed ID: 30522358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Feng J; Sun X; Sun N; Qin S; Li F; Cheng H; Chen B; Cao Y; Ma J; Cheng L; Lu Z; Ji J; Zhou Y
    Acta Biochim Biophys Sin (Shanghai); 2009 May; 41(5):429-35. PubMed ID: 19430706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polymorphisms in the XRCC1 gene are associated with treatment response to platinum chemotherapy in advanced non-small cell lung cancer patients based on meta-analysis.
    Li L; Wan C; Wen FQ
    Genet Mol Res; 2014 May; 13(2):3772-86. PubMed ID: 24938464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
    Ryu JS; Hong YC; Han HS; Lee JE; Kim S; Park YM; Kim YC; Hwang TS
    Lung Cancer; 2004 Jun; 44(3):311-6. PubMed ID: 15140544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. XRCC3 Thr241Met is associated with response to platinum-based chemotherapy but not survival in advanced non-small cell lung cancer.
    Qiu M; Xu L; Yang X; Ding X; Hu J; Jiang F; Xu L; Yin R
    PLoS One; 2013; 8(10):e77005. PubMed ID: 24116196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis.
    Wei SZ; Zhan P; Shi MQ; Shi Y; Qian Q; Yu LK; Song Y
    Med Oncol; 2011 Mar; 28(1):315-21. PubMed ID: 20143185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis.
    Yin M; Yan J; Voutsina A; Tibaldi C; Christiani DC; Heist RS; Rosell R; Booton R; Wei Q
    Lung Cancer; 2011 Jun; 72(3):370-7. PubMed ID: 21075476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between the XRCC1 polymorphisms and clinical outcomes of advanced NSCLC treated with platinum-based chemotherapy: a meta-analysis based on the PRISMA statement.
    Li DJ; Xiao D
    BMC Cancer; 2017 Jul; 17(1):501. PubMed ID: 28743242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ERCC1 and BRCA1 mRNA expressions are associated with clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
    Qin X; Yao W; Li W; Feng X; Huo X; Yang S; Zhao H; Gu X
    Tumour Biol; 2014 May; 35(5):4697-704. PubMed ID: 24443257
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The 5'UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs.
    Rulli E; Guffanti F; Caiola E; Ganzinelli M; Damia G; Garassino MC; Piva S; Ceppi L; Broggini M; Marabese M
    Sci Rep; 2016 Dec; 6():39217. PubMed ID: 27966655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Significant Statistical Advancement on the Predictive Values of ERCC1 Polymorphisms for Clinical Outcomes of Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: An Updated Meta-Analysis.
    Han Y; Liu J; Sun M; Zhang Z; Liu C; Sun Y
    Dis Markers; 2016; 2016():7643981. PubMed ID: 27057082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Association of the responsiveness of advanced non-small cell lung cancer to platinum-based chemotherapy with p53 and p73 polymorphisms].
    Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Zhang XR; Sun Y; Xu BH; Lin DX
    Zhonghua Zhong Liu Za Zhi; 2006 Feb; 28(2):107-10. PubMed ID: 16750013
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Zhao J; Chen S; Zhou H; Zhang T; Liu Y; He J; Zhu J; Ruan J
    Aging (Albany NY); 2018 May; 10(5):1073-1088. PubMed ID: 29779017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.